Gustave Roussy, Cancer Campus, Grand Paris

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that haven't responded to standard treatments. The study will closely…

This study tests whether adding the chemotherapy drug carboplatin to standard treatment can help men with a fast-growing type of prostate cancer that has spread. The cancer must have a BRCA gene mutation or show neuroendocrine features. About 330 men will receive either standard …

This phase 3 trial tests whether adding chemotherapy after surgery can prevent aggressive pancreatic neuroendocrine tumors from coming back. About 300 people who had their tumor fully removed will either receive active surveillance alone or six cycles of capecitabine and temozolo…

This study tests whether the HPV vaccine can prevent the return of high-grade precancerous lesions in people who have already been treated for them. About 984 participants aged 18 to 55 with HPV-related lesions in the cervix, vulva, vagina, penis, or anus will receive either the …

This study tests whether a CBD oil solution can reduce joint pain caused by hormone therapy (aromatase inhibitors) in people with early-stage, hormone-receptor-positive breast cancer. About 130 participants will receive either CBD or a placebo, then switch treatments to compare e…

This study will follow 1,100 people with advanced neuroendocrine tumors (NETs) to see which treatments or treatment sequences cause the fewest long-term, limiting side effects. Participants are newly diagnosed or have not yet started treatment. The goal is to create a tool that h…

This study explores whether a digital tool using extended reality (like virtual reality) can help teenagers and young adults who have finished treatment for testicular cancer. Many survivors face long-term physical or emotional challenges that are often overlooked. The tool is de…